Question

Compare non-viral vs. viral vectors in gene therapy, their advantages/disadvantages, and applications in treating cystic fibrosis, hemophilia, cancer, and dermatological disorders.

29 Jan 2026
Answer :
Word Count : 529
Gene therapy relies on efficient delivery systems to introduce therapeutic genes into target cells, broadly classified into viral and non-viral vectors. These two systems differ significantly in structure, efficiency, safety, and scope of application, influencing their suitability for treating genetic and acquired disorders such as cystic fibrosis, hemophilia, cancer, and dermatological diseases. Viral vectors are derived from genetically modified viruses such as adenovirus, adeno-associated virus (AAV), retrovirus, and lentivirus, in which pathogenic genes are removed and replaced with therapeutic DNA. Their major advantage lies in high transfection efficiency, as viruses have evolved natural mechanisms to enter host cells and deliver genetic material. Viral vectors can achieve stable or long-term gene expression, particularly integrating vectors like retroviruses and lentiviruses, which is beneficial for inherited disorders. However, they present several disadvantages, including immunogenicity, risk _______ ________ _________ ______ _____ _________ ______ ______ ___ ________.
__________ _______ _____ ________ __________ ________ _________ ___ ___ _________ ______.
____ _____ ___ ___ _____ _____ _______ ________ __________ __________ ____ ____.
_______ __________ __________ ________ ____ ________ ______ __________ ________.
_____ _________ _________ _______ ____ _______ _________ __________ ______ __________ ________.
__________ ______ ___ _____ ___ ____ _______ __________ ______.
____ __________ ____ ______ _______.
______ _____ ________ ____ ______ __________ ___ __________ _____ __________.
__________ _______ __________ ________ _________ ___ _______.
____ ____ ________ ___ _________ ___ _______.
_______ ______ ___ __________ __________ _______ __________ ______ _____.
________ _______ ______ ______ _____ _____ ____ ____ ________ ___.
________ _______ _______ _______ ______ ____ _________ ______ ________ __________.
__________ __________ ___ _______ _____ ____ ______ _________.
________ _______ _________ _______ _________ _______ ______.
__________ __________ ____ ______ _________ ___ ____ ______ ________.
__________ _________ ______ ________ ______ ____ ______ ______ __________ __________ __________ ________.
_____ __________ __________ _____ _____ __________ __________ ____ ________.
___ ____ __________ ____ ______ __________ _______ ______ ______.
________ ____ _________ ___ ___.
_____ ___ ______ ___ _________ ____ _______ ________ ____.
_____ ___ __________ ______ _______.
____ ___ _____ __________ ____ _____ ________ ___ _________ ____.
__________ _____ _____ _______ _____ ______ ______ ___ _____ _____.
______ __________ ____ ____ ______ _______ ______ _______ _______ _____ _______ __________.
____ _______ ______ ___ _________ _____ ________ ____ __________ _______.
___ __________ _____ ____ ________ ________.
_____ ____ ______ ____ ________ _________ _______.
________ ___ ___ ________ __________.
________ ___ __________ _______ __________ ___ ______.
________ ________ ___ _________ ___ _____ ____ ____.
_________ ______ _________ ___ _______ __________ _______ __________ ______ ________ __________.
___ ___ ___ ___ __________ ______ ___.
___ ____ _______ ______ ________ ______ ______ _____ _______ _______ _________ _______.
__________ _______ _______ ____ __________ ____ ________ _______ ____ _________.
____ _______ _____ ________ _____ __________.
_________ __________ ________ ________ ______ ______ __________ ________ _____ ____ ___.
________ _________ ________ ____ _________ ____ _____ _______.
___ __________ ___ ________ ___ ____.
________ ___ ___ _______ ________ _______ ________ _______ ________.
______ ________ _________ __________ _____.
______ ___ __________ _______ _____ ___.
____ ______ ___ ___ ____ ___ _________ ____.
__________ __________ _________ _________ ______ ______ _______ __________ _____ _____ _____.
______ __________ _________ ________ ____ _________ ___ _____ ___ ___ _______.
____ ___ ____ _________ __________ ___ ______ _________.
Get Full Answer on WhatsApp
IGNOU NEWS
Assignment Submission Last Date Extended Till 30 June 2026 Click Here★★★IGNOU June 2026 TEE Date Sheet Released Click Here★★★
Top
📞
Call Support Instant phone assistance Compare non-viral vs. viral vectors in gene therapy, their advantages/
→
🟢
WhatsApp Chat Fast live messaging
→
Email Us Business enquiries & support
→